Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study

Amer Zeidan, Anthony Selwyn Stein, Johanna Rimpiläinen, Marja Pyörälä, Timo Siitonen, Brian Ball, Mikko Myllymäki, Joshua Zeidner, Dr. Emma Searle, Ruth Witherall, Petri Bono, Aneel Nimba, Joab Williamson, Sofia Aakko, Maija Hollmén, Mika Kontro, Naval Daver

Blood (2025) 146 (Supplement 1): 236.

https://doi.org/10.1182/blood-2025-236

Published: 2025

Journal Articles

Dynamics of leukemic blast and immune cell populations in Acute Myeloid Leukemia

Sadiksha Adhikari, Philipp Sergeev, Nemo Ikonen, Minna Suvela, Heikki Kuusanmäki, Mika Kontro, Markus Vaha-Koskela, Caroline Heckman

Blood (2025) 146 (Supplement 1): 3490.

https://doi.org/10.1182/blood-2025-3490

Published: 2025

Journal Articles

Transfusion independence, hematological improvement and associated safety outcomes with bexmarilimab and azacitidine in HR-MDS: Results of the bexmab Phase 1/2 study

Mika Kontro, Anthony Selwyn Stein, Johanna Rimpiläinen, Marja Pyörälä, Timo Siitonen, Brian Ball, Mikko Myllymäki, Joshua Zeidner, Dr. Emma Searle, Ruth Witherall, Petri Bono, Aneel Nimba, Joab Williamson, Sofia Aakko, Maija Hollmén, Amer Zeidan, Naval Daver

Blood (2025) 146 (Supplement 1): 5627.

https://doi.org/10.1182/blood-2025-5627

Published: 2025

Journal Articles

Functional drug response profiling predicts clinical outcomes and shows utility for treatment stratification in AML

Blood (2025) 146 (Supplement 1): 1716.

https://doi.org/10.1182/blood-2025-1716

Published: 2025

Journal Articles

Anti-TIM3 with hypomethylating agent revives NK and cytotoxic CD4+ T cell activity in patients with AML or MDS

Blood (2025) 146 (Supplement 1): 1704.

https://doi.org/10.1182/blood-2025-1704

Published: 2025

Journal Articles

Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)

Blood (2025) 146 (Supplement 1): 1654.

https://doi.org/10.1182/blood-2025-1654

Published: 2025

Journal Articles

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Sarah Bertoli, Niklas Landberg, Emilie Bérard, Camille Gondran, Laetitia Largeaud, Véronique De Mas, Pierre-Yves Dumas, Arnaud Pigneux, Audrey Bidet, Sylvain Garciaz, Ludovic Gabellier, Gabrielle Roth-Guepin, Corentin Orvain, Pierre Peterlin, Rudy Birsen, Magda Alexis, Martin Carre, Emmanuelle Tavernier, Marion Boissard Simonet, Chantal Himberlin, Marc Maynadié, Kamel Laribi, Cécile Moluçon-Chabrot, Amine Belhabri, Samy Chraibi, Quentin Cabrera, Delphine Lebon, Emmanuel Raffoux, Thomas Cluzeau, Jean-Baptiste Micol, Mathieu Leclerc, Céline Berthon, Herve Dombret, Gunnar Juliusson, Anna Robelius, Sören Lehmann, Martin Jädersten, Lovisa Wennström, Pau Montesinos, Carmen Botella, Juan Miguel Bergua Burgues, Raimundo Garcia, Josefina Serrano, Mariluz Amigo, Patricia Garcia Ramirez, Claudia Sossa, Juan Manuel Alonso-Dominguez, Hartmut Döhner, Konstanze Döhner, Daniela Späth, Michael Kühn, Claudia Lengerke, Hans-Jörg Tischler, Christoph Röllig, Leo Ruhnke, Christian Thiede, Andreas Burchert, Hubert Serve, Carsten Mueller-Tidow, Claudia Baldus, Jurjen Versluis, Peter Valk, Daniel Kristensen, Anne Stidsholt Roug, Jiri Mayer, Mika Kontro, Pia Ettala, Vladimir Lazarevic, Christian Recher

Blood (2025) 146 (Supplement 1): 991.

https://doi.org/10.1182/blood-2025-991

Published: 2025

Journal Articles

Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial

Blood (2025) 145 (4): 409–421.

https://doi.org/10.1182/blood.2024024968

Published: 2025

Includes: Supplemental data

Journal Articles

Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia

Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh B. Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman

Blood (2024) 144 (Supplement 1): 1560.

https://doi.org/10.1182/blood-2024-207199

Published: 2024

Journal Articles

Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML

Henri Sundquist, Mikael Tatun, Mikko Purhonen, Laura Toivanen, Johanna Rimpiläinen, Samuli Rounioja, Timo Siitonen, Marja Pyörälä, Pentti Mäntymaa, Sari Kytölä, Kimmo Porkka, Sanna Siitonen, Heikki Kuusanmäki, Mika Kontro, Oscar E. Brück

Blood (2024) 144 (Supplement 1): 4320.

https://doi.org/10.1182/blood-2024-206949

Published: 2024

Journal Articles

Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study

Mika Kontro, Anthony S. Stein, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Jenna H Rannikko, Jesper Mickos, Rita Turpin, Milja Hakoniemi, Birge Berns, Sofia Aakko, Inka Pawlitzky, Maija Hollmén, Amer M. Zeidan, Naval Daver

Blood (2024) 144 (Supplement 1): 4265.

https://doi.org/10.1182/blood-2024-206804

Published: 2024

Journal Articles

Integrative Analysis of Transcriptomic and Proteomic Data Identifies Patterns of Primary Resistance to Venetoclax-Azacitidine and Reveals Targetable Vulnerabilities in Acute Myeloid Leukemia (AML)

Ida Vänttinen, Joseph Saad, Tanja Ruokoranta, Sari Kytölä, Pia-Sofia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Caroline A. Heckman, Heikki Kuusanmäki, Mika Kontro

Blood (2024) 144 (Supplement 1): 2757.

https://doi.org/10.1182/blood-2024-209429

Published: 2024

Journal Articles

Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes

Sofia Forstén, Livius Penter, Oscar E. Brück, Johannes Smolander, Karita Peltonen, Harri Lähdesmäki, Mika Kontro, Kimmo Porkka, Hussein A. Abbas, Catherine J. Wu, Jani Huuhtanen, Satu Mustjoki

Blood (2024) 144 (Supplement 1): 1529.

https://doi.org/10.1182/blood-2024-199471

Published: 2024

Journal Articles

Encouraging Efficacy Observed in Bexmab Study: A Phase 1/2 Study to Assess Safety and Efficacy of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies

Mika Kontro, Anthony Selwyn Stein, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Maija Hollmén, Marie-Louise Fjaellskog, Inka Pawlitzky, Amer M. Zeidan, Naval Daver

Blood (2023) 142 (Supplement 1): 2915.

https://doi.org/10.1182/blood-2023-174912

Published: 2023

Journal Articles

Targeting Venetoclax Resistance in TP53 -Mutated Acute Myeloid Leukemia

Ida Vänttinen, Tanja Ruokoranta, Joseph J Saad, Sari Kytölä, Monica Hellesøy, Stein-Erik Gullaksen, Pia-Sofia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Krister Wennerberg, Bjorn T. Gjertsen, Caroline A. Heckman, Mika Kontro, Heikki Kuusanmäki

Blood (2023) 142 (Supplement 1): 2927.

https://doi.org/10.1182/blood-2023-189340

Published: 2023

Journal Articles

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

Blood (2023) 141 (13): 1610–1625.

https://doi.org/10.1182/blood.2021011094

Published: 2023

Includes: Supplemental data

Journal Articles

Monosomy 7 and Del(7q) Cause Selective Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia

Joseph Saad, Samuli Eldfors, Vilma Ikonen, Bjørn Tore Gjertsen, Mika Kontro, Kimmo Porkka, Caroline A. Heckman

Blood (2022) 140 (Supplement 1): 1033–1035.

https://doi.org/10.1182/blood-2022-163242

Published: 2022

Journal Articles

Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 101–103.

https://doi.org/10.1182/blood-2022-158694

Published: 2022

Journal Articles

Trial in Progress: A Phase I/II Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination with Standard of Care in Patients with Hematological Malignancies (BEXMAB)

Inka Pawlitzky, Timo Siitonen, Naval Daver, Juho Jalkanen, Sofia Aako, Marie-Louise Fjällskog, Mika Kontro

Blood (2022) 140 (Supplement 1): 11751–11752.

https://doi.org/10.1182/blood-2022-156786

Published: 2022

Journal Articles

Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax

Blood (2022) 140 (Supplement 1): 2020–2022.

https://doi.org/10.1182/blood-2022-159391

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study

Dynamics of leukemic blast and immune cell populations in Acute Myeloid Leukemia

Transfusion independence, hematological improvement and associated safety outcomes with bexmarilimab and azacitidine in HR-MDS: Results of the bexmab Phase 1/2 study

Functional drug response profiling predicts clinical outcomes and shows utility for treatment stratification in AML

Anti-TIM3 with hypomethylating agent revives NK and cytotoxic CD4+ T cell activity in patients with AML or MDS

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial

Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia

Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML

Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study

Integrative Analysis of Transcriptomic and Proteomic Data Identifies Patterns of Primary Resistance to Venetoclax-Azacitidine and Reveals Targetable Vulnerabilities in Acute Myeloid Leukemia (AML)

Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes

Encouraging Efficacy Observed in Bexmab Study: A Phase 1/2 Study to Assess Safety and Efficacy of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies

Targeting Venetoclax Resistance in TP53 -Mutated Acute Myeloid Leukemia

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

Monosomy 7 and Del(7q) Cause Selective Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia

Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia

Trial in Progress: A Phase I/II Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination with Standard of Care in Patients with Hematological Malignancies (BEXMAB)

Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only